



OFFICE OF MAILING

I hereby certify that this paper and every
paper referred to therein as being enclosed
is being deposited with the U.S. Postal
Service as first class mail, postage prepaid,
in an envelope addressed to: Commissioner of
Patents and Trademarks, Washington, D.C. 20231,
on December 9, 1996 (Date of Deposit)

#7

12/9/96 A. Stanton
Date Name

1010/16959 US4

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:

Howard L. WEINER et al.

Serial No: 08/469,492

Group Art Unit: 1813

Filed: June 6, 1995

Examiner: B. Prickril

For: **BYSTANDER SUPPRESSION OF AUTOIMMUNE DISEASE**

RECEIVED
DEC 26 1996
GROUP 1800

Honorable Commissioner of
Patents and Trademarks
Washington, D.C. 20231

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Sir:

In order to comply with discretionary regulations 37 CFR §§ 1.97 and 1.98,
attached hereto is Form PTO-1449. Copies¹ of the documents listed thereon can be found in

¹To the extent that a document is listed and no copy of same is attached, then such document is not at the present time available to the undersigned or is available in the file of a parent application. If a listed document is not in the English language and an English translation is readily available, such translation is also attached; if translation is not attached it is not readily available to the undersigned. If a foreign language patent document is cited, and an English language equivalent is known to the undersigned, then such equivalent patent is also cited on the attached form along with the corresponding foreign language patent and a connecting arrow indicated therebetween; if no such English language equivalent is cited, then none is known to the undersigned.

the file of related application, U.S. Serial Number 08/472,017[^]. These documents contain information which the Examiner may consider to be important in deciding whether to allow the present application to issue as a patent and which were cited with respect to European Patent Number 0 359 783 B1. This Information Disclosure Statement should be considered by the office under 37 CFR § 1.97 (c).


In accordance with MPEP Sections 609 and 707.05(b), it is requested that each document cited (including any cited in applicant's specification which is not repeated on the attached Form PTO-1449) be given thorough consideration and that it be cited of record in the prosecution history of the present application by initialing on Form PTO-1449. Such initialing is requested even if the Examiner does not consider a cited document to be sufficiently pertinent to use in a rejection, or otherwise does not consider it to be prior art for any reason, or even if the Examiner does not believe that the guidelines for citation have been fully complied with. This is requested so that each document becomes listed on the face of the patent issuing on the present application.

The present Disclosure Statement is being submitted in compliance with 37 CFR 1.56 insofar as an Examiner might consider any of the cited documents important in deciding whether to allow the application to issue as a patent, but the citation of each document is not to be construed as an admission that such document is necessarily relevant or prior art. No representation is intended that the cited documents represent the results of a complete search, and it is anticipated that the Examiner, in the normal course of examination, will make an independent search and will determine the best prior art consistent

with 37 CFR 1.104(a) and 1.106(b) and, in the course of each search, will review for relevance every document cited on the attached form even if not initialed.

Early and favorable consideration is earnestly solicited.

Respectfully submitted,



Seth H. Jacobs
Registration No. 32,140
Attorney for Applicant(s)

DARBY & DARBY P.C.
805 Third Avenue
New York, N.Y. 10022
(212) 527-7700